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Abstract
Background: The triad of quality, innovation and economic restraint is as important in health care
as it is in the business world. There are many proposals for the assessment of quality and of
economic restraints in health care but only a few address assessment of innovations. We propose
a strategy and new structures to standardize the description of health care innovations and to
quantify them.
Discussion: Strategy and structure are based on the assumption that in the early phase of an
innovation only data on the feasibility and possibly on the efficacy or effectiveness of an innovation
can be expected. From the patient's perspective, benefit resulting from an innovation can be
confirmed only in a later phase of development. Early indicators of patient's benefit will be
surrogate parameters which correlate only weakly with the desired endpoints. After the innovation
has been in use, there will be more evidence on correlations between surrogate parameters and
the desired endpoints to provide evidence of the patient benefit. From an administrative
perspective, this evidence can be considered in decisions about public financing. Different criteria
are proposed for the assessment of innovations in prevention, diagnosis and therapy. For decisions
on public financing a public fund for innovations may be helpful. Depending on the phase of
innovation risk sharing models are proposed between manufacturers, private insurers and public
funding.
Summary: Potential for patient benefit is always uncertain during early stages of innovations. This
uncertainty decreases with increasing information on the effects of the innovation. Information
about an innovation can be quantified, categorized and integrated into rational economic decisions.
Background
The triad of quality, innovation, and economic restraint is
as important in the provision of healthcare as it is in the
business world. In economics, an innovation refers not
only to products (like therapies and diagnostic measures),
but also to procedures and the development of new mar-
kets [1]. Transferring this understanding of innovation to
a publicly-financed system is risky because forces that gov-
ern the free market are often not feasible in a publicly-
financed system. We do not have a good understanding of
how systems innovations can systematically, fairly, and
transparently be transferred to healthcare provision. A
Canadian proposal describes innovation in the healthcare
system as the replacement of a previous method with a
new approach that provides sustainable and competitive
benefit. Benefit is sustainable and competitive if it keeps
the organization economically healthy, introduces a rare
or singular characteristic, and contains a learning process
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which enables the organization to achieve a leading posi-
tion in the market [2].
According to the Veterans Affairs Health System, quality can-
not be separated from innovation. Research results are
immediately integrated into everyday clinical practice to
either improve patient care or to increase the efficiency of the
system [3]. Also the British National Institute for Health and
Clinical Excellence (NICE) is confronted with a similar prob-
lem. It has to make well-balanced decisions among quality,
innovation, and value for money [4]). In Germany we are in
the stage of developing a similar system. A rapid transfer of
innovation to the daily provision of healthcare must be com-
bined with a critical test of its validity. If a new method does
not fulfill expectations, a search for a better method to
replace it is likely. However, these examples are exceptions.
In many countries practices, once introduced, may get con-
tinuing application without ongoing evaluation. In the
United States as well as in Germany, the Food and Drug
Administration (FDA) in the U.S. and the corresponding
authority in Germany requires that pharmaceutical firms
maintain phase IV monitoring studies. However, the con-
cern in these evaluations is in both countries surveillance for
harm, rather than continuing evaluation of efficacy. Lack of
efficacy may be considered as economic harm.
Access to provision of healthcare innovations is ultimately
regulated by reimbursement policies. This dichotomous
decision to fund or not fund a particular innovation is
problematic because of the benefit of the intervention is
often uncertain. Such uncertainty creates two risks in these
decisions – either healthcare services of little benefit are
publicly financed or access to highly beneficial healthcare
services is denied. It is difficult to exclude publicly-
financed services which have been supported and promot-
ing untested innovations is associated with far-reaching
risks. We believe it is necessary to have regulation which
minimizes both risks, the undesired financing of services
of little benefit and the undesired curbing of innovations.
Uncoupling consumers from medical progress and loss of
the stimulating effect on competition are among the far-
reaching risks of curbing innovation.
To reduce uncertainty in decision-making about public
support of innovative treatments, standardized cost-bene-
fit and cost-utility assessments of healthcare services
should be required whenever possible. The methodical
drawbacks of these procedures are well known, but are
accepted because they still improve the decision process.
Since this discussion, including the value assessment of
new medications, is ongoing in Germany, many parties
have suggested accepting the internationally recognized
standard (with its known deficiencies) while simultane-
ously working on improved acceptable solutions [5,6].
Comparing innovations is challenging because the benefit
of different innovations cannot be evaluated with identi-
cal criteria. The evaluation of preventive measures [7] and
of diagnostic measures [8] requires considerations which
are too complex and too far removed from an acceptable
solution to be applied in a standardized way. These limi-
tations should be taken into consideration to avoid over-
estimating the practical relevance of criteria which we
apply to assess innovations. We illustrate this with exam-
ples from prevention and diagnosis.
A preventive measure will be considered valuable if the
achievement of the desired endpoint (like avoiding late
consequences of a metabolic syndrome) can actually be
confirmed. The benefit will be valued less highly if it can
be proved that surrogate markers closely correlated with
the endpoint (like a significant reduction in body mass
index) is attained and maintained. If, however, there are
no data describing the chances or attaining the endpoint,
the benefit of this innovation will be considered small.
Diagnostic measures also require a discriminating evalua-
tion because the benefit to the patient deriving from the
diagnosis depends on a successful intervention for the
problem that has been diagnosed. A number of hurdles lie
between a correct diagnosis and a successful resolution of
the problem in everyday clinical practice, like deducing
the correct diagnostic result, correctly managing the
accompanying illnesses, and achieving high patient com-
pliance. In everyday practice it is rarely recognized that
each of these hurdles must be successfully overcome to
reach the desired goal. Intermediate goals are extremely
important, but are not sufficient to serve as the basis of a
benefit-oriented allocation of resources [9].
The solution may lie in a compromise – dividing the
assessment of innovations into two parts, the evaluation
of less and of more complex problems. Less complex
problems could be evaluated by statements upon which
agreement can be reached and which are considered to be
supported by scientific theory and evidence. Complex
problems cannot be solved by descriptions and explana-
tions because there is no way to get the unequivocal evi-
dence. They can only be solved by norms such as
recommendations, guidelines or laws. These norms can-
not be prescribed by scientists. Norms require delibera-
tion beyond the scientific process and must include the
public and policy makers. We refer to this process as dem-
ocratic authorization. We as scientists shall herein restrict
ourselves to suggestions for solving simpler problems,
which can be supported by true, scientific statements.
We propose qualitative assessment of innovations in
healthcare provision, although we are well aware that anBMC Health Services Research 2009, 9:50 http://www.biomedcentral.com/1472-6963/9/50
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evaluation of innovations, just as evaluation of the benefit
of healthcare services, concerns normative, but not "true",
statements and requires democratic authorization.
Discussion
Qualitative Instead of Dichotomous Assessment of 
Innovations
Clinical decisions on innovations are problematic
because we are uncertain whether the assumed advantages
will materialize and the expected disadvantages will
remain within the set limits. The data that justify the deci-
sions are often unavailable before most medicines are
licensed.
The risk of making incorrect decisions can be reduced if
the final decision can be delayed until relevant data are
available and a provisional decision based on existing
information is offered. The better the available data the
less will be the risk. The decisive factor is information that
is based on the results and not on structures or processes
which, in the final analysis, describe the quality of patient
care. This point of view, which contains the three compo-
nents, is shared by Portuguese authors [10], e.g., in "Ino-
vacão, Evidencia e Mondo Real" (Innovation, Evidence,
and the Real World), which describes the innovative idea,
the data which confirm its feasibility, and the result
obtained under everyday conditions.
Public Agency
We propose that new public agencies are required to over-
see the funding of innovations. Current strategies have
serious limitations. For example, the United States Food
and Drug Administration primarily focussed on safety.
Although they do require some continuing monitoring of
pharmaceutical products, the FDA does not provide
enough information for the comparison of relative effec-
tiveness. Further, the FDA does not consider cost-effective-
ness or many components of patient reported wellness.
One concern with contemporary approaches is that con-
flicts of interest are common. For example, members of
committees that create guidelines often receive financial
support from companies that make the products they are
evaluating [11,12].
We propose national agencies similar to the National
Institute for Health and Clinical Excellence (NICE). These
agencies would focus on clinical effectiveness and would
require specific components in their evaluation. The agen-
cies would provide clinical information and outcomes
study evaluations long after products are licensed. Com-
ponents of the evaluations would include clinical out-
come studies, evaluations of the relevance of the outcome
measures, and cost-utility assessments. Based on these
data the agency would also make prioritization recom-
mendations but no effective decisions for publicly sup-
ported programs. The effective decisions about public
health care services have to be made by an agency with
democratic authorization. Guidelines would be available
to private payers who could make their own decisions
about whether or not to apply the guidelines.
The public agencies would draw on peer review panels of
experts and would have very strict conflict of interest dis-
closure requirements.
Components of Decision Process Used by Agencies
These three components can be allocated to two dimen-
sions which we believe are appropriate to classify innova-
tions. The two dimensions concern the positive
perspective and the uncertainty about expected risks and
benefits (Fig. 1).
The expectation-uncertainty-diagram of innovations Figure 1
The expectation-uncertainty-diagram of innova-
tions. Positive expectations in an innovation as well as 
uncertainty of data (as assessed by validity and variance of 
results) are rated on a scale ranging from zero to 1. Four 
possible results are shown. Red dot: Too positive expecta-
tions but too much uncertainty; this constellation is not con-
sidered as innovation. Mixed colour dots: The green/yellow 
innovation is ranked higher than the red/yellow innovation 
because less positive expectation combined with less uncer-
tainty is higher ranked than more positive expectation com-
bined with more uncertainty. Green dot: the combination of 
positive expectation with low uncertainty is considered as 
innovation. T: threshold.
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The positive perspective, expressing the power of motiva-
tion [13-15], is the most important criterion of innova-
tion. An innovation is attractive if it offers the prospective
of a solution to a hitherto unsolved problem. The greater
the belief that the new innovation will offer benefit, the
greater will be the demand for the promised solution. Not
infrequently however, the need and desire to offer a new
therapeutic principle will motivate the use of interven-
tions that are not accompanied by convincing data.
On several occasions it is impossible to separate placebo
effects [13] on one hand from the desired increase in
motivation i.e. directing the patient towards the attain-
ment of her/his goal [15]. A simple experiment performed
at the Massachusetts Institute of Technology [16] helps
illustrate this point. Students were randomly assigned to
be informed that they had received an expensive pain-
killer or a cheaper version of the same painkiller. All of the
subjects then received the same level of electric shock.
Those told they had received the expensive medication
perceived the shock as considerably weaker than their
peers who believed they had taken the cheaper pill. Since
both groups had actually been given placebos, this exper-
iment confirms that the reality we perceive is substantially
influenced by information and value judgments (e.g.,
expensive = better). The ethical evaluation of this experi-
ment could influence its acceptance. We got the impres-
sion that colleagues who considered this experiment to be
ethically problematic evaluated the information gained as
less important than colleagues who accepted the ethical
problem involved in this experiment. Those colleagues
who accepted the terms of the experiment assume that the
gain in information about the power of the placebo effect
compensates the ethical problem because many incorrect
conclusions could be avoided by this information, and
risks to patients could thereby be reduced.
In summary, interest in an innovation increases the chances
that the innovation will be evaluated positively. Rational
considerations predict that the information, which induces a
positive perspective, may not be evidence-based and may
often lack validity. Neither the doctor who generates the pos-
itive perspective nor the patient who requests the positive
perspective will be motivated to seek objective information
that may discredit their faith in the innovation. Skepticism
about the value of the innovation would destroy its power to
mediate the positive perspective.
The second dimension of innovation is related to uncer-
tainty of the results. In principle, it is relatively irrelevant
whether the uncertainty is due to insufficient validity of
the data or variability of the results. The important point
is that only few reliable data are available at the time when
a decision to either accept or reject an innovation must be
made. In this case an attempt is made to use the few relia-
ble data to support a statement that represents the best
knowledge at the time the decision is being made
Description of Steps in Innovation
Since innovations in prevention, diagnosis, and therapy
cannot be evaluated according to identical criteria, for the
sake of clarity we are listing them separately, even if that
inevitably leads to repetition. The individual steps in
innovation differ in the information available to support
its benefit and are different in preventive (Table 1), diag-
nostic (Table 2) and therapeutic innovations (Table 3).
￿ In the first step of innovation, only data on the effi-
cacy and on the feasibility of a measure would be
required.
￿ The second step would require confirmation of the
benefit of the innovation with surrogate parameters
which may only weakly correlate with the desired end-
points.
￿ The third step, would require a high correlation
between the surrogate parameters and the desired end-
points, i.e. evidence that the benefit of the innovation
is sufficiently probable to justify public financing.
Financing Innovations
Justification for public financing of an innovation would
require the steps outlines in Table 4. This evidence would
be reviewed by the impartial public agency described
above.
Table 1: Description of the steps in preventive innovations with examples.
Step Preventive innovation Example
I Preliminary data confirm the optimization of the application of a 
preventive measure.
Improved tolerance, lower cost, or easier application of 
preventive measures.
II Preventive benefit can be expected under everyday conditions due 
to high acceptance of the preventive measure.
High level of participation in the prevention program.
III Preventive benefit can be expected under everyday conditions due 
to the proof surrogate parameters which are not only temporary.
Clinical results are achieved which hitherto could not be 
achieved without this prevention program.BMC Health Services Research 2009, 9:50 http://www.biomedcentral.com/1472-6963/9/50
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Assessment and support of innovations increases the effi-
ciency of a healthcare system because resources would be
directed toward those innovations that have the highest
probability of producing benefit. This leads to a desired
redistribution of the available resources. When evaluating
innovations, the break even point, which is considered
appropriate by society, must be identified. This is the
threshold that identifies levels of benefit that the public is
willing to pay for [17].
The program would require the creation of a special set
aside fund to finance higher risk innovations. Partial
financing could provide important information about the
willingness of the insured to pay, and a comparative value
judgment could be obtained. However, this information
can only be gained at the expense of at least temporary,
unequal access to this innovation. It is also possible to
obtain information concerning willingness to pay on the
part of healthcare providers. A risk-sharing model ori-
ented to the expected successes of the innovation could be
applied here. For reasons of fairness in decision making,
either both forms of information gain or neither should
be accepted.
In the interest of competition, the extent of financing can-
not be determined prospectively. It will depend on the
amount of available financial resources, the quality of the
innovation, the intensity of the demand, and the willing-
ness of the public to pay.
Practical implications
The steps in innovation describe the phases of informa-
tion gain concerning the benefit of an innovation. In the
beginning of these phases the only data available concern
the effectiveness and the safety of the innovation. Data on
benefit are typically not available. Safety and efficacy can
Table 2: Description of the steps in diagnostic innovations with examples.
Step Diagnostic innovation Example
I Preliminary data confirm an improvement in the feasibility or the 
results of diagnostic procedures (likelihood radio) in clinical studies.
Improved tolerance, easier application, or improved result of a 
diagnostic pro-cedurea.
II Diagnostic benefit can be expected under everyday conditions 
due to the influence of the test result on the strategy of healthcare 
provisionb.
It will be sufficient if the new diagnostic procedure enables a new 
therapeutic approach (independent of the success of this therapy).
III Diagnostic benefit is confirmed under everyday conditions if a 
patient group can be identified that profits more than other groups 
from an available therapy.
The diagnostic innovation will be valuable if it enables a new 
therapy and this new therapy will be effective e.g. it improves 
QoL.
aUncontested improvement in diagnosis does not guarantee improvement in treatment results. The quality of healthcare provision can be lowered 
by a growing gap between diagnostic and therapeutic possibilities. For this reason, isolated diagnostic successes are evaluated with caution. 
bInfluence on the strategy of healthcare provision means that the test result either influences the further diagnostic strategy or crosses the 
threshold from diagnosis to therapy. Influence on diagnostic strategy is confirmed if a positive test result leads to different diagnostic procedures 
than a negative test result.
Table 3: Description of the steps in therapeutic innovations with examples.
Step Therapeutic innovation Example
I Preliminary data confirm optimized 
application of a therapeutic procedure. 
Only data on effect and safety from 
clinical studies are available.
Improved tolerance, lower cost, or easier application of therapeutic procedures.
II Therapeutic benefit can be expected 
under everyday conditions due to a 
weak correlation of surrogate 
parametersa with desired endpoints.
Reduction of tumor size after chemotherapy with unknown influence on quality of life or 
survival.
III Therapeutic benefit is confirmed 
under everyday conditions by 
surrogate parameters which correlate 
highly with the desired endpoint(s) or 
achievement of endpoints.
Improvement in a defined area of quality of life or survival is confirmed.
aIf surrogate parameters correlate only weakly, there is only a weak correlation between the confirmation of those surrogate parameters and the 
actually desired endpoint(s).BMC Health Services Research 2009, 9:50 http://www.biomedcentral.com/1472-6963/9/50
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justify licensure of an innovation but may not be enough
to endorse public funding. Whether or not the innovation
should be financed from public funds can only be decided
when its benefit can be confirmed by a continuous gain in
information. The goal of the innovation scale is to bridge
this interval of indecision. It should ensure that promising
innovations are available to all citizens, but remain pub-
licly affordable.
Whether we approve of competition or not, stakeholders
will decide which innovation prevails when the service of
a different provider on the international market is better
and more economical than that which the domestic pro-
vider can offer. Stakeholders can be the patients or pur-
chasers of goods and services [18]. Technical and
commercial services will be evaluated according to differ-
ent quality criteria than services which place high
demands on communication and the supply of specialist
competence. It is, therefore, appropriate to work out crite-
ria to assess the value of healthcare services and to place
these in relation to costs [19]. Teleradiology and telepa-
thology are services for which it should be relatively easy
to develop uniform quality criteria for innovations.
It will be considerably more difficult to determine which
methods should be used to decide whether something
new should be recognized as an innovation. One recent
debate considered whether the NICE Health Technology
Assessment of therapy of the attention deficit/hyperactiv-
ity disorder (ADHD) met the demands of a well-balanced
evaluation because NICE's economic model is dominated
by cost differences [20,21]. This decision is relatively sim-
ple in comparison to the questions of why quantitative
research is preferred to qualitative research and the tech-
niques are subject to a hierarchic value judgment [22]. We
know from experience that cultural differences, whether
evidence based or not, are reality to patients, families and
physicians. This is also true for innovations and the differ-
ences in recognizing them in different cultural circles. We
need more discussion of criteria applied in different cul-
tures to make decisions concerning the allocation of
resources for innovations.
Finally, even a qualitative assessment of innovative
healthcare services cannot conceal that successful reorgan-
ization of the system, which is often necessary for the
implementation of innovations, involves the coordina-
tion and management of a complex process and not
merely the realization of an isolated project [23].
Summary
Quantitative assessment of innovations may be a helpful
step for economic decisions about innovations
We propose a three step model based on the best available
information at different developmental stages of the inno-
vation evaluation process
Decision about reimbursement should be based on
reviews by an impartial outcomes assessment agency
A public fund should be established to support evidence-
based innovations.
An example is presented to illustrate how risk sharing
models between manufacturers, private insurers, and the
public fund can be adapted as new data on efficiency and
effectiveness become available.
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Table 4: Proposed model for agreement on goal and limited financial support of innovations
Step Limited financial support Agreement on goal
I Partial financing by risk sharing between the manufacturer and public 
fund for innovations.
The partners agree to strive for partial financing by private insurer 
and public fund.
II Partial financing by private insurer and public fund for innovations. The partners agree to strive for financing by a public fund for 
innovation.
III Financing by public fund for innovations. Elimination of remaining uncertain results by enlarging the 
database.
After agreement has been reached on specific goals, innovations which have not yet been included in publicly-financed healthcare are financed by a 
public fund for innovations for a defined amount of time. Depending on the extent to which proposed goals have been achieved, inclusion in 
publicly-financed healthcare provision will be determined at the end of the period of financing from the innovation fund.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Health Services Research 2009, 9:50 http://www.biomedcentral.com/1472-6963/9/50
Page 7 of 7
(page number not for citation purposes)
References
1. Schumpeter JA: Business Cycles: A Theoretical, Historical, and
Statistical Analysis of the Capitalist Process.  1st edition.
McGraw-Hill Book Company, Inc., New York and London; 1939. 
2. Macdonald M: Quality, Innovation, and Cost Containment.
Can Nurse 1993, 89:15-17.
3. Kizer KW, Demakis JG, Feussner JR: Reinventing VA Health Care
– Systematizing Quality improvement and Quality innova-
tion.  Medical Care 2000, 38:1-7.
4. Pearson SD, Rawlins MD: Quality, Innovation, and Value for
Money. NICE and the British National Health Service.  JAMA
2005, 294:2618-2622.
5. Jönsson B: IQWiG: an opportunity lost?  Eur J Health Econ 2008,
9:205-207.
6. Krauth C, John J, Aidelsburger P, Brüggenjürgen B, Hansmeier T, Hes-
sel F, Kohlmann T, Moock J, Rothgang H, Schweikert B, Seitz R,
Wasem J, AG Methoden der gesundheitsökonomischen Evaluation:
Comments by the Working Group for Methods of Economic
Evaluation in Health Care (AG MEG) to IQWiG's Draft
Guidelines "Methods for Assessment of the Relation of Ben-
efits to Costs in the German Statutory Health Care System
[Abstract in English].  Gesundheitswesen 2008, 70:1-16.
7. Porzsolt F, Kirner A, Kaplan RM: Predictors of Successful Cancer
prevention Programs.  Recent Results Cancer Res 2009, 181:19-31.
8. Stengel D, Porzsolt F: Efficacy, Effectiveness and Efficiency of
Diagnostic Technology.  In Optimizing Health – Improving the Value
of Healthcare Delivery Edited by: Porzsolt F, Kaplan RM. Springer, New
York; 2006:217-231. 
9. Battalio RC, Kagel JH, Jiranyakul K: Testing between alternative
models of choice under uncertainty: Some initial results.  J
Risk Uncertainty 1990, 3:25-50.
10. Uva MS: Innovation, evidence and the real world. A surgeon's
perspective on the treatment of three-vessel or left main
coronary artery disease with drug-eluting stents.  Rev Port Car-
diol 2007, 26:1199-1211.
11. Choudhry NK, Stelfox HAT, Detsky AS: Relationship between
authors of clinical practice guidelines and the pharmaceuti-
cal industry.  JAMA 2002, 287:612-617.
12. Ridker PM, Torres J: Reported outcomes in major cardiovascu-
lar clinical trials funded by for-profit and not-for-profit
organizations: 2000–2005.  JAMA 2006, 295:2270-2274.
13. Barrett B, Rakel D, Chewning B, Marchand L, Rabago D, Brown R,
Scheder J, Schmidt R, Gern JE, Bone K, Thomas G, Barlow S, Bobula
J: Rationale and methods for a trial assessing placebo, echina-
cea, and doctor-patient interaction in the common cold.
Explore (NY) 2007, 3:561-572.
14. Choi BC, Pak AW: Multidisciplinarity, interdisciplinarity, and
transdisciplinarity in health research, services, education
and policy: 2. Promotors, barriers, and strategies of
enhancement.  Clin Invest Med 2007, 30(6):E224-E232.
15. Knight KM, McGowan L, Dickens C, Bundy C: A systematic review
of motivational interviewing in physical health care settings.
Br J Health Psychol 2006, 11:319-332.
16. Waber RL, Shiv B, Carmon C, Ariely D: Commercial features of
placebo and therapeutic efficacy.  JAMA 2008, 299:1016-1017.
17. Woolf SH, Johnson RE: The Break-Even Point: When Medical
Advances Are Less Important Than Improving the Fidelity
With Which They Are Delivered.  Ann Fam Med 2005,
3:545-552.
18. Sing SN, Wachter RM: Perspectives on Medical Outsourcing
and Telemedicine – Rough Edges in a Flat World?  N Engl J Med
2008, 358:1622-1627.
19. Porter ME, Teisberg EO: How physicians can change the future
of health care.  JAMA 2007, 297:1103-1111.
20. Schlander M: Has NICE got it right? An international perspec-
tive considering the case of Technology Appraisal No. 98 by
the National Institute for Health and Clinical Excellence
(NICE).  Curr Med Res Opin 2008, 24:951-966.
21. Schlander M: The NICE ADHD health technology assessment:
A review and critique.  Child Adolesc Psychiatry Ment Health 2008,
2:1-9.
22. Lambert H: Accounting for EBM: Notions of evidence in med-
icine.  Soc Sci Med 2006, 62(11):2633-2645.
23. Wang MC, Hyun JK, Harrison MI, Shortell SM, Fraser I: Redesigning
health systems for quality: lessons from emerging practices.
Jt Comm J Qual Patient Saf 2006, 32(11):599-611.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1472-6963/9/50/prepub